目的 探讨止嗽化痰丸联合奥马环素治疗肺炎支原体肺炎的临床疗效。方法 选取2022年8月—2024年7月天津医科大学附属宝坻医院收治的肺炎支原体肺炎患者120例，按随机数字表法将患者分为对照组和治疗组，每组各60例。对照组患者静脉输注注射用甲苯磺酸奥马环素，第1天将200 mg溶于250 mL生理盐水，1次/d，第2天开始以100 mg/次，1次/d的维持剂量治疗。在对照基础上，治疗组睡前口服止嗽化痰丸，15丸/次，1次/d。两组患者治疗10 d。观察两组患者临床疗效，比较治疗前后两组患者主症消失时间，肺炎严重指数（PSI）、睡眠状况自评量表（SRSS）和36项健康调查简表（SF-36）评分，及中性粒细胞与淋巴细胞比值（NLR）、红细胞沉降率（ESR）、C反应蛋白（CRP）和补体C3水平。结果 治疗后，治疗组总有效率明显高于对照组（96.67% vs 86.67%，P＜0.05）。治疗后，治疗组咳痰、胸闷痛、咳嗽、肺部啰音、发烧消失时间均短于对照组（P＜0.05）。治疗后，两组PSI、SRSS评分低于组内治疗前，而SF-36评分显著增加（P＜0.05），且治疗组评分明显好于对照组（P＜0.05）。治疗后，两组NLR、ESR和血清CRP、补体C3水平都低于同组治疗前（P＜0.05），且治疗组这些指标水平均低于对照组（P＜0.05）。结论 在奥马环素基础上联合止嗽化痰丸治疗可有效提高肺炎支原体肺炎的临床疗效，能较为安全的调节机体免疫炎症状态，促进患者症状、病情缓解及睡眠与生活质量的改善。

Objective To explore the clinical efficacy of Zhisou Huatan Pills combined with omacycline in treatment of mycoplasma pneumoniae pneumonia. Methods Patients (120 cases) with mycoplasma pneumoniae pneumonia in Baodi Hospital Affiliated to Tianjin Medical University from August 2022 to July 2024 were divided into control group and treatment group according to random number table method, with 60 cases in each group. Patients in control group were iv administered with Omadacycline Tosilate for injection, 200 mg was dissolved into 250 mL normal saline on the first day, once daily, and a maintenance dose was administered with 100 mg/time from the second day, once daily. Patients in treatment group were po administered with Zhisou Huatan Pills on the basis of the control group, 15 pills/time, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluations were evaluated, and the disappearance time of main symptoms, PSI, SRSS, and SF-36 scores, and NLR, ESR, serum CRP, and complement C3 levels in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was significantly higher than that in the control group (96.67% vs 86.67%, P < 0.05). After treatment, the disappearance time of expectoration, chest tightness and pain, cough, pulmonary rales and fever in treatment group was shorter than that in control group (P < 0.05). After treatment, the PSI and SRSS scores in two groups were lower than those before treatment, while the SF-36 score was significantly increased (P < 0.05), and the scores in the treatment group were significantly better than that in the control group (P < 0.05). After treatment, the levels of NLR, ESR, serum CRP and complement C3 in two groups were lower than those before treatment in the same group (P < 0.05), and the levels of these indicators in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of omacycline and Zhisou Huatan Pills can effectively improve the clinical efficacy of mycoplasma pneumoniae pneumonia, safely regulate the immune inflammatory state, promote symptom relief, and improve sleep and quality of life in patients.

R974